News

CalciMedica Raises $21 Million in Series D Financing to support the clinical development of CRAC channel inhibitors

BY      |     March 12, 2021

CalciMedica, a clinical-stage biotechnology company developing CRAC inhibitors for the treatment of inflammatory diseases, announced it has raised $21 Million in Series D Financing to support the clinical development of a portfolio of CRAC channel inhibitors including AuxoraTM which is being evaluated in an ongoing clinical trial in severe and critical COVID-19 pneumonia, and in a Phase 2b trial in acute pancreatitis.

Auxora is currently under evaluation in a blinded, placebo-controlled clinical trial enrolling up to 400 patients with severe and critical COVID-19 pneumonia. To date over 200 patients have been randomized. Patients are receiving either Auxora or matched placebo in addition to standard of care, which includes dexamethasone and may include remdesivir.

Read the press release here.

Read more about CalciMedica here.



Photo by Fusion Medical Animation on Unsplash


Comments? Questions? Suggestions?

If you have any comments, questions or suggestions concerning this article, feel free to email me at [email protected]
Alternatively, you can leave your comments on LinkedIn or Twitter.